TY - JOUR
T1 - Induction of Epstein-Barr virus oncoprotein LMP1 by transcription factors AP-2 and early B cell factor
AU - Murata, Takayuki
AU - Noda, Chieko
AU - Narita, Yohei
AU - Watanabe, Takahiro
AU - Yoshida, Masahiro
AU - Ashio, Keiji
AU - Sato, Yoshitaka
AU - Goshima, Fumi
AU - Kanda, Teru
AU - Yoshiyama, Hironori
AU - Tsurumi, Tatsuya
AU - Kimura, Hiroshi
N1 - Funding Information:
We thank W. Hammerschmidt, H. J. Delecluse, and S. W. Tsao for providing the EBV-BAC system, HEK293 cells, and C666-1 cells. We also are grateful to K. Miyazono, F. Hayakawa, and Sigvardsson for the AP-2 PAX5, and EBF expression vectors. This study was supported by grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology (to T.T. [23390118 and 23114512], T.M. [15K08494], Y.N. [14J01982], and H.K. [25293109]); the Ministry of Health, Labor, and Welfare (to T.T.); the Japan Agency forMedical Research and Development (to H.K. [Practical Research Project for Rare/Intractable Diseases, 15ek0109098]); and partly by the UeharaMemorial Research Fund, the Takeda Science Foundation (to T.T. and T.M.), the SenshinMedical Research Foundation, the Kanae Foundation for the Promotion of Medical Science, the General Assembly of the Japanese Association ofMedical Sciences (to T.M.), and a Grant for the Joint Research Program of the Institute for Genetic Medi-cine, Hokkaido University (to T.T., T.K., and H.Y.). Japan Agency forMedical Research and Development (AMED) provided funding to Hiroshi Kimura under grant number 15ek0109098. Senshin Medical Research Foundation provided funding to TakayukiMurata. Kanae Foundation for Promotion of Medical Science provided funding to TakayukiMurata. General Assembly of the Japanese Association of Medical Sciences provided funding to Takayuki Murata. Institute for Genetic Medicine, Hokkaido University provided funding to Teru Kanda, Hironori Yoshiyama, and Tatsuya Tsurumi.Ministry of Education, Culture, Sports, Science, and Technology (MEXT) provided funding to Takayuki Murata, YoheiNarita, Tatsuya Tsurumi, andHiroshi Kimura under grant numbers 23390118, 23114512, 15K08494, 14J01982, and 25293109. Takeda Science Foundation provided funding to Takayuki Murata and Tatsuya Tsurumi.Ministry of Health, Labour andWelfare (MHLW) provided funding to Tatsuya Tsurumi. Uehara Memorial Foundation provided funding to Takayuki Murata and Tatsuya Tsurumi.
Publisher Copyright:
© 2016, American Society for Microbiology.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Latent membrane protein 1 (LMP1) is a major oncogene essential for primary B cell transformation by Epstein-Barr virus (EBV). Previous studies suggested that some transcription factors, such as PU.1, RBP-Jκ, NF-κB, and STAT, are involved in this expression, but the underlying mechanism is unclear. Here, we identified binding sites for PAX5, AP-2, and EBF in the proximal LMP1 promoter (ED-L1p). We first confirmed the significance of PU.1 and POU domain transcription factor binding for activation of the promoter in latency III. We then focused on the transcription factors AP-2 and early B cell factor (EBF). Interestingly, among the three AP-2-binding sites in the LMP1 promoter, two motifs were also bound by EBF. Overexpression, knockdown, and mutagenesis in the context of the viral genome indicated that AP-2 plays an important role in LMP1 expression in latency II in epithelial cells. In latency III B cells, on the other hand, the B cell-specific transcription factor EBF binds to the ED-L1p and activates LMP1 transcription from the promoter.
AB - Latent membrane protein 1 (LMP1) is a major oncogene essential for primary B cell transformation by Epstein-Barr virus (EBV). Previous studies suggested that some transcription factors, such as PU.1, RBP-Jκ, NF-κB, and STAT, are involved in this expression, but the underlying mechanism is unclear. Here, we identified binding sites for PAX5, AP-2, and EBF in the proximal LMP1 promoter (ED-L1p). We first confirmed the significance of PU.1 and POU domain transcription factor binding for activation of the promoter in latency III. We then focused on the transcription factors AP-2 and early B cell factor (EBF). Interestingly, among the three AP-2-binding sites in the LMP1 promoter, two motifs were also bound by EBF. Overexpression, knockdown, and mutagenesis in the context of the viral genome indicated that AP-2 plays an important role in LMP1 expression in latency II in epithelial cells. In latency III B cells, on the other hand, the B cell-specific transcription factor EBF binds to the ED-L1p and activates LMP1 transcription from the promoter.
UR - http://www.scopus.com/inward/record.url?scp=84963787374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84963787374&partnerID=8YFLogxK
U2 - 10.1128/JVI.03227-15
DO - 10.1128/JVI.03227-15
M3 - Article
C2 - 26819314
AN - SCOPUS:84963787374
SN - 0022-538X
VL - 90
SP - 3873
EP - 3889
JO - Journal of Virology
JF - Journal of Virology
IS - 8
ER -